High-Throughput CRISPR Screening in Hematological Neoplasms
CRISPR is becoming an indispensable tool in biological research, revolutionizing diverse fields of medical research and biotechnology. In the last few years, several CRISPR-based genome-targeting tools have been translated for the study of hematological neoplasms. However, there is a lack of reviews...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/15/3612 |
| _version_ | 1797442668573229056 |
|---|---|
| author | Raquel Ancos-Pintado Irene Bragado-García María Luz Morales Roberto García-Vicente Andrés Arroyo-Barea Alba Rodríguez-García Joaquín Martínez-López María Linares María Hernández-Sánchez |
| author_facet | Raquel Ancos-Pintado Irene Bragado-García María Luz Morales Roberto García-Vicente Andrés Arroyo-Barea Alba Rodríguez-García Joaquín Martínez-López María Linares María Hernández-Sánchez |
| author_sort | Raquel Ancos-Pintado |
| collection | DOAJ |
| description | CRISPR is becoming an indispensable tool in biological research, revolutionizing diverse fields of medical research and biotechnology. In the last few years, several CRISPR-based genome-targeting tools have been translated for the study of hematological neoplasms. However, there is a lack of reviews focused on the wide uses of this technology in hematology. Therefore, in this review, we summarize the main CRISPR-based approaches of high throughput screenings applied to this field. Here we explain several libraries and algorithms for analysis of CRISPR screens used in hematology, accompanied by the most relevant databases. Moreover, we focus on (1) the identification of novel modulator genes of drug resistance and efficacy, which could anticipate relapses in patients and (2) new therapeutic targets and synthetic lethal interactions. We also discuss the approaches to uncover novel biomarkers of malignant transformations and immune evasion mechanisms. We explain the current literature in the most common lymphoid and myeloid neoplasms using this tool. Then, we conclude with future directions, highlighting the importance of further gene candidate validation and the integration and harmonization of the data from CRISPR screening approaches. |
| first_indexed | 2024-03-09T12:45:18Z |
| format | Article |
| id | doaj.art-d9591c79be144e50881f7b404091e66f |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T12:45:18Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d9591c79be144e50881f7b404091e66f2023-11-30T22:13:14ZengMDPI AGCancers2072-66942022-07-011415361210.3390/cancers14153612High-Throughput CRISPR Screening in Hematological NeoplasmsRaquel Ancos-Pintado0Irene Bragado-García1María Luz Morales2Roberto García-Vicente3Andrés Arroyo-Barea4Alba Rodríguez-García5Joaquín Martínez-López6María Linares7María Hernández-Sánchez8Department of Translational Hematology, Instituto de Investigación Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, CIBERONC, ES 28041 Madrid, SpainDepartment of Biochemistry and Molecular Biology, Pharmacy School, Universidad Complutense de Madrid, ES 28040 Madrid, SpainDepartment of Translational Hematology, Instituto de Investigación Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, CIBERONC, ES 28041 Madrid, SpainDepartment of Translational Hematology, Instituto de Investigación Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, CIBERONC, ES 28041 Madrid, SpainDepartment of Biochemistry and Molecular Biology, Pharmacy School, Universidad Complutense de Madrid, ES 28040 Madrid, SpainDepartment of Translational Hematology, Instituto de Investigación Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, CIBERONC, ES 28041 Madrid, SpainDepartment of Translational Hematology, Instituto de Investigación Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, CIBERONC, ES 28041 Madrid, SpainDepartment of Translational Hematology, Instituto de Investigación Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, CIBERONC, ES 28041 Madrid, SpainDepartment of Biochemistry and Molecular Biology, Pharmacy School, Universidad Complutense de Madrid, ES 28040 Madrid, SpainCRISPR is becoming an indispensable tool in biological research, revolutionizing diverse fields of medical research and biotechnology. In the last few years, several CRISPR-based genome-targeting tools have been translated for the study of hematological neoplasms. However, there is a lack of reviews focused on the wide uses of this technology in hematology. Therefore, in this review, we summarize the main CRISPR-based approaches of high throughput screenings applied to this field. Here we explain several libraries and algorithms for analysis of CRISPR screens used in hematology, accompanied by the most relevant databases. Moreover, we focus on (1) the identification of novel modulator genes of drug resistance and efficacy, which could anticipate relapses in patients and (2) new therapeutic targets and synthetic lethal interactions. We also discuss the approaches to uncover novel biomarkers of malignant transformations and immune evasion mechanisms. We explain the current literature in the most common lymphoid and myeloid neoplasms using this tool. Then, we conclude with future directions, highlighting the importance of further gene candidate validation and the integration and harmonization of the data from CRISPR screening approaches.https://www.mdpi.com/2072-6694/14/15/3612CRISPRhematological neoplasmslibrariesalgorithmsresistancesvulnerabilities |
| spellingShingle | Raquel Ancos-Pintado Irene Bragado-García María Luz Morales Roberto García-Vicente Andrés Arroyo-Barea Alba Rodríguez-García Joaquín Martínez-López María Linares María Hernández-Sánchez High-Throughput CRISPR Screening in Hematological Neoplasms Cancers CRISPR hematological neoplasms libraries algorithms resistances vulnerabilities |
| title | High-Throughput CRISPR Screening in Hematological Neoplasms |
| title_full | High-Throughput CRISPR Screening in Hematological Neoplasms |
| title_fullStr | High-Throughput CRISPR Screening in Hematological Neoplasms |
| title_full_unstemmed | High-Throughput CRISPR Screening in Hematological Neoplasms |
| title_short | High-Throughput CRISPR Screening in Hematological Neoplasms |
| title_sort | high throughput crispr screening in hematological neoplasms |
| topic | CRISPR hematological neoplasms libraries algorithms resistances vulnerabilities |
| url | https://www.mdpi.com/2072-6694/14/15/3612 |
| work_keys_str_mv | AT raquelancospintado highthroughputcrisprscreeninginhematologicalneoplasms AT irenebragadogarcia highthroughputcrisprscreeninginhematologicalneoplasms AT marialuzmorales highthroughputcrisprscreeninginhematologicalneoplasms AT robertogarciavicente highthroughputcrisprscreeninginhematologicalneoplasms AT andresarroyobarea highthroughputcrisprscreeninginhematologicalneoplasms AT albarodriguezgarcia highthroughputcrisprscreeninginhematologicalneoplasms AT joaquinmartinezlopez highthroughputcrisprscreeninginhematologicalneoplasms AT marialinares highthroughputcrisprscreeninginhematologicalneoplasms AT mariahernandezsanchez highthroughputcrisprscreeninginhematologicalneoplasms |